1980
Established in the 1980’s, SGC is now dedicated in Hema-technology through Transfusion Safety& Regenerative Medicine.
1989
Began Leukocyte Reduction Filter Set Development.
2009
Safetran BioMedical Inc. a spin-off company from SGC(established 1980). Pilot plant (Taipei, Taiwan) established
2010
ISO 13485 granted.
2014
LRF of WB/PRBC approved by Taiwan Blood Service Foundation.
2015
Phoenix ® Autologous Bio-active Molecules Enrich System commercially launched with CE approval as 2nd class medical device.
Phoenix ® Autologous Bio-active Molecules Enrich System applied in Orthopedics treatments.
2017
Safetran ® Leukocyte reduction filter served to Taiwan Blood Bank.
2018
ISO/CE certification granted by BSI.
Novelty membrane project acheived successfully.
Phoenix ® Autologous Bio-active Molecules Enrich System applied in Sports Medicine treatments by Olympic team doctors of Taiwan.
2019
Rhea® Launched into Ophthalmology medicine.
Novelty Membrane patent pending.
Mass production project kick-off.
2020
The pilot plant of Sangtech got GMP.
2022
The commercial plant of Green Membrane completed.
Green Membrane of Sangtech was shortlisted for R&D 100 Awards.
To be continued
Established in the 1980’s, SGC is now dedicated in Hema-technology through Transfusion Safety& Regenerative Medicine.